España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Moleculin Biotech
MBRX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$1.54
-0.01
-0.65%
At close: -
$1.59
0.05
3.13%
After Hours: 6:07 PM EDT
Get Report
Comment
Moleculin Biotech (MBRX) Forecast
News
Earnings
Moleculin Biotech (MBRX) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Moleculin Biotech (NASDAQ:MBRX) Stock
Moleculin Biotech Stock (NASDAQ: MBRX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, January 17, 2025
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
Wednesday, January 08, 2025
Moleculin Biotech shares are trading higher a...
Benzinga Newsdesk
Moleculin Biotech Received U.S. Institutional...
Benzinga Newsdesk
Wednesday, December 11, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
What's Going On With Moleculin Biotech Shares Wednesday?
Dylan Berman
Moleculin Biotech shares are trading higher a...
Benzinga Newsdesk
Moleculin Announces Online Publication Of Pre...
Benzinga Newsdesk
Monday, November 18, 2024
Moleculin Biotech Announces New Findings Sup...
Benzinga Newsdesk
Thursday, November 14, 2024
Moleculin Biotech shares are trading higher a...
Benzinga Newsdesk
Moleculin Amends Clinical Trial Protocol With...
Benzinga Newsdesk
Tuesday, November 12, 2024
Maxim Group Maintains Buy on Moleculin Biotec...
Benzinga Newsdesk
Moleculin Biotech shares are trading higher a...
Benzinga Newsdesk
Moleculin Receives Institutional Review Board...
Benzinga Newsdesk
Monday, November 11, 2024
Moleculin Biotech Q3 2024 GAAP EPS $(2.85) Mi...
Benzinga Newsdesk
Thursday, November 07, 2024
Insights Ahead: Moleculin Biotech's Quarterly Earnings
Benzinga Insights
Monday, September 23, 2024
Moleculin Biotech shares are trading higher a...
Benzinga Newsdesk
Moleculin Biotech Presents Data On Annamycin ...
Benzinga Newsdesk
Monday, September 09, 2024
Moleculin Biotech Announces Enrollment And Tr...
Benzinga Newsdesk
Friday, August 16, 2024
Moleculin Biotech shares are trading lower af...
Benzinga Newsdesk
Moleculin Biotech Announces Pricing Of Public...
Benzinga Newsdesk
Wednesday, August 14, 2024
Moleculin Biotech shares are trading higher a...
Benzinga Newsdesk
Moleculin Biotech Q2 EPS $(1.70) Beats $(2.31...
Benzinga Newsdesk
Thursday, August 01, 2024
Moleculin Announces Plans For MIRACLE Adaptiv...
Benzinga Newsdesk
Wednesday, July 10, 2024
Moleculin Biotech Completes End Of Phase 2 Me...
Benzinga Newsdesk
Friday, June 14, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
Moleculin Reports Additional Preliminary Inte...
Benzinga Newsdesk
Friday, June 07, 2024
Moleculin Biotech Files For Mixed Shelf Offer...
Benzinga Newsdesk
Wednesday, May 15, 2024
Moleculin Commences NIH-Funded Phase 2 Clinic...
Benzinga Newsdesk
Friday, May 10, 2024
Moleculin Biotech Q1 EPS $(2.02) Beats $(3.53...
Benzinga Newsdesk
Thursday, May 09, 2024
Moleculin Biotech Received Issue Notification...
Benzinga Newsdesk
Tuesday, May 07, 2024
Moleculin Reports Higher AML Complete Remissi...
Benzinga Newsdesk
Wednesday, May 01, 2024
Moleculin Announces Formation Of Scientific A...
Benzinga Newsdesk
Friday, April 26, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
Thursday, April 18, 2024
European Medicines Agency Grants Orphan Drug ...
Benzinga Newsdesk
Friday, April 12, 2024
Roth MKM Maintains Buy on Moleculin Biotech, ...
Benzinga Newsdesk
Wednesday, April 10, 2024
Moleculin Presents Data For Anthracycline
Benzinga Newsdesk
Monday, April 08, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
Wednesday, March 27, 2024
Moleculin Received U.S. Patent Issue Notifica...
Benzinga Newsdesk
Tuesday, March 26, 2024
Maxim Group Maintains Buy on Moleculin Biotec...
Benzinga Newsdesk
Monday, March 25, 2024
Moleculin Biotech shares are trading lower af...
Benzinga Newsdesk
Moleculin Biotech Provided A Preliminary Upda...
Benzinga Newsdesk
Friday, March 22, 2024
Moleculin Biotech FY23 EPS $(15.07) Vs $(15.2...
Benzinga Newsdesk
Trading Halt: Halt status updated at 8:55:00 ...
Benzinga Newsdesk
Earnings Scheduled For March 22, 2024
Benzinga Insights
Thursday, March 21, 2024
Trading Halt: Halted at 7:50:00 p.m. ET - Tra...
Benzinga Newsdesk
A Preview Of Moleculin Biotech's Earnings
Benzinga Insights
Wednesday, March 20, 2024
Micron, Signet Jewelers And 3 Stocks To Watch Heading Into Wednesday
Avi Kapoor
Tuesday, March 19, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
Moleculin Biotech shares are trading higher. ...
Benzinga Newsdesk
Moleculin Announces 1-For-15 Reverse Stock Sp...
Benzinga Newsdesk
Show More
